These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37368258)

  • 1. An Overview of the Use of Nanoparticles in Vaccine Development.
    Lozano D; Larraga V; Vallet-Regí M; Manzano M
    Nanomaterials (Basel); 2023 Jun; 13(12):. PubMed ID: 37368258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
    Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
    ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 vaccine development and a potential nanomaterial path forward.
    Shin MD; Shukla S; Chung YH; Beiss V; Chan SK; Ortega-Rivera OA; Wirth DM; Chen A; Sack M; Pokorski JK; Steinmetz NF
    Nat Nanotechnol; 2020 Aug; 15(8):646-655. PubMed ID: 32669664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine process technology.
    Josefsberg JO; Buckland B
    Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    ArXiv; 2023 Jan; ():. PubMed ID: 36034485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could live attenuated vaccines better control COVID-19?
    Okamura S; Ebina H
    Vaccine; 2021 Sep; 39(39):5719-5726. PubMed ID: 34426024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current view on novel vaccine technologies to combat human infectious diseases.
    Matić Z; Šantak M
    Appl Microbiol Biotechnol; 2022 Jan; 106(1):25-56. PubMed ID: 34889981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
    Cavanagh D
    Avian Pathol; 2003 Dec; 32(6):567-82. PubMed ID: 14676007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
    Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
    Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M
    J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications.
    Prabhakar PK; Khurana N; Vyas M; Sharma V; Batiha GE; Kaur H; Singh J; Kumar D; Sharma N; Kaushik A; Kumar R
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review.
    Sandoval C; Guerrero D; Muñoz J; Godoy K; Souza-Mello V; Farías J
    Expert Rev Vaccines; 2023; 22(1):35-53. PubMed ID: 36484136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent approaches to mRNA vaccine delivery by lipid-based vectors prepared by continuous-flow microfluidic devices.
    Toudeshkchouei MG; Tavakoli A; Mohammadghasemi H; Karimi A; Ai J; Rabiee M; Rabiee N
    Future Med Chem; 2022 Nov; 14(21):1561-1581. PubMed ID: 36300415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
    Elia U; Rotem S; Bar-Haim E; Ramishetti S; Naidu GS; Gur D; Aftalion M; Israeli M; Bercovich-Kinori A; Alcalay R; Makdasi E; Chitlaru T; Rosenfeld R; Israely T; Melamed S; Abutbul Ionita I; Danino D; Peer D; Cohen O
    Nano Lett; 2021 Jun; 21(11):4774-4779. PubMed ID: 34032435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development.
    Ilyichev AA; Orlova LA; Sharabrin SV; Karpenko LI
    Vavilovskii Zhurnal Genet Selektsii; 2020 Nov; 24(7):802-807. PubMed ID: 33959697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
    Wang C; Zhang Y; Dong Y
    Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dawn of mRNA vaccines: The COVID-19 case.
    Verbeke R; Lentacker I; De Smedt SC; Dewitte H
    J Control Release; 2021 May; 333():511-520. PubMed ID: 33798667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.